Denmark Supplementary Protection Certificates

Supplementary Protection Certificates

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Country	Patent Number	Supplementary Protection Certificate	SPC Country	SPC Description	SPC Expiration
European Patent Office	2506716	CA 2020 00011	Denmark	PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
European Patent Office	1586571	CA 2014 00011	Denmark	PRODUCT NAME: ALOGLIPTIN; REG. NO/DATE: EU/1/13/844/001-027 20130919
European Patent Office	3204015	CA 2022 00011	Denmark	PRODUCT NAME: LUMASIRAN EVENTUELT I FORM AF ET SALT; REG. NO/DATE: EU/1/20/1496 20201123
European Patent Office	2334687	CA 2018 00025	Denmark	PRODUCT NAME: ERTUGLIFLOZIN, EVENTUELT SOM EN KRYSTALFORM, SAERLIGT SOM ET CO-KRYSTAL MED L-PYROGLUTAMINSYRE OG SPECIFIKT SOM ERTUGLIFLOZIN-L-PYROGLUTAMINSYRE; NAT. REG. NO/DATE: EU/1/18/1267/001-012 20180323; FIRST REG. NO/DATE: EU EU/1/18/1267/001/012 20180323
European Patent Office	2666774	CR 2020 00037	Denmark	PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
European Patent Office	2435432	CR 2017 00021	Denmark	PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207